US FDA Approves New Parkinson’s Drug
The US Food and Drug Administration has approved AbbVie’s treatment for Parkinson’s disease in adults. The drug, tavapadon, was acquired … Read More The post US FDA Approves New Parkinson’s Drug appeared first on ProPakistani .
The US Food and Drug Administration has granted approval to AbbVie's innovative treatment for Parkinson's disease in adults. This groundbreaking drug, tavapadon, was acquired by AbbVie through their acquisition of Cerevel Therapeutics in 2023, which totaled $8.7 billion. The medication will be marketed under the brand name Juvmo.
Juvmo is a once-daily oral medication designed for patients with Parkinson's disease, a chronic brain condition that progressively impairs movement control and may lead to tremors, stiffness, and balance difficulties. According to AbbVie, over 11 million individuals globally are affected by this debilitating disease. The drug functions by imitating dopamine, a crucial brain chemical that naturally diminishes in those with Parkinson's disease.
The FDA's endorsement was predicated on data from AbbVie's extensive late-stage trial program, which demonstrated the efficacy of the medicine in alleviating symptoms for patients. Common adverse reactions observed in these trials encompassed nausea, dizziness, and headaches. As of the current date, AbbVie has not disclosed any information regarding the drug's launch strategy or pricing.
Analysts from Citi had previously anticipated the launch to commence in the third quarter of 2026, with implementation likely to be gradual due to ongoing Medicare coverage negotiations.
Written by urgent.news from ProPakistani's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
